C4 Therapeutics, Inc. (CCCC)

Import this data to Google Sheets with:

=jivedata("CCCC","financials")

Full statements spill as a table. For one cell: =jivedata("CCCC","Revenue") or =jivedata("CCCC","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

C4 Therapeutics, Inc.

CCCC • CIK 0001662579

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$20,756	$35,584	$35,947	$35,039
Operating Income (Loss)	$-139,031	$-119,614	$-115,222	$-111,765
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-131,213	$-105,185	$-104,873	$-104,873
Income Tax Expense (Benefit)	$1,280	$131	$121	$121
Net Income (Loss) Attributable to Parent	$-132,493	$-105,316	$-104,994	$-101,416
Weighted Average Number of Shares Outstanding, Basic	49,640,505	69,372,993	82,894,459	140,373,005
Research and Development Expense	$117,706	$110,637	$104,240	$100,048
General and Administrative Expense	$42,081	$42,124	$36,196	$36,023
Restructuring Charges	—	$2,437	$0	$0
Operating Expenses	$159,787	$155,198	$151,169	$146,804
Interest and Other Income	$9,812	$14,429	$10,349	$10,470
Nonoperating Income (Expense)	$7,818	$14,429	$10,349	$10,470
Marketable Securities, Unrealized Gain (Loss)	$4,010	$180	$-3	$-365
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-128,483	$-105,136	$-104,997	$-101,830
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	—	—	117,739,718	219,308,982

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$126,590	$55,499	$74,603	$78,610
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	$127,091	$189,405	$173,934	$175,053
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	$28,008	$22,359	$48,563	$46,786
Accounts Receivable, after Allowance for Credit Loss, Current	$11,799	$3,102	$2,401	$1,334
Property, Plant and Equipment, Net	$7,132	$5,842	$4,744	$4,149
Prepaid Expense and Other Assets, Current	$5,709	$9,761	$7,172	$7,905
Operating Lease, Right-of-Use Asset	$63,956	$57,536	$40,532	$37,637
Assets, Current	$271,189	$257,767	$258,110	$262,902
Restricted Cash and Cash Equivalents, Noncurrent	$3,443	$3,443	$3,443	$3,443
Other Assets, Noncurrent	$2,723	$2,655	$3,683	$4,487
Assets	$376,451	$349,602	$359,075	$359,404
Contract with Customer, Liability, Noncurrent	$21,814	$28,457	$15,841	$13,714
Operating Lease, Liability, Noncurrent	$65,757	$59,982	$53,615	$50,178
Liabilities	$130,337	$133,616	$102,488	$112,139
Accounts Payable, Current	$1,446	$1,328	$858	$1,121
Accrued Liabilities and Other Liabilities	$20,630	$19,363	$13,314	$13,785
Contract with Customer, Liability, Current	$15,471	$18,712	$12,493	$26,661
Operating Lease, Liability, Current	$5,219	$5,774	$6,367	$6,680
Liabilities, Current	$42,766	$45,177	$33,032	$48,247
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$6	$7	$9	$12
Additional Paid in Capital, Common Stock	$774,618	$849,625	$995,221	$1,035,154
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-127	$53	$50	$-444
Retained Earnings (Accumulated Deficit)	$-528,383	$-633,699	$-738,693	$-787,457
Stockholders' Equity Attributable to Parent	$246,114	$215,986	$256,587	$247,265
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	150,000,000	150,000,000	300,000,000	300,000,000
Common Stock, Shares, Issued	60,467,188	70,625,899	96,914,418	122,905,756

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$97,000	$-71,091	$19,104	$453
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$130,033	$58,942	$78,046	$88,027
Net Income (Loss) Attributable to Parent	$-132,493	$-105,316	$-104,994	$-101,416
Net Cash Provided by (Used in) Operating Activities	$-106,838	$-65,157	$-98,694	$-84,870
Proceeds from Sale and Maturity of Marketable Securities	$289,955	$233,231	$219,080	$216,609
Payments to Acquire Marketable Securities	$129,898	$284,321	$227,074	$291,395
Payments to Acquire Property, Plant, and Equipment	$1,708	$180	$607	$523
Net Cash Provided by (Used in) Investing Activities	$158,349	$-51,270	$-8,601	$-75,309
Proceeds from Issuance of Common Stock	$57,673	—	—	—
Proceeds from Stock Options Exercised	$58	$778	$107	$888
Payments for Repurchase of Common Stock	$110	$194	$193	$238
Proceeds from (Payments for) Other Financing Activities	$368	$382	$274	$221
Net Cash Provided by (Used in) Financing Activities	$45,489	$45,336	$126,399	$160,632
Restricted Cash and Cash Equivalents	$3,443	$3,443	$3,443	$3,443
Cash and Cash Equivalents, at Carrying Value	$126,590	$55,499	$74,603	$84,584
Share-based Payment Arrangement, Noncash Expense	$27,235	$29,662	$19,099	$14,307
Depreciation, Depletion and Amortization, Nonproduction	$1,880	$1,818	$1,959	$1,959
Operating Lease, Right-of-Use Asset, Amortization Expense	$6,159	$6,421	$6,434	$6,012
Accretion (Amortization) of Discounts and Premiums, Investments	$3,784	$5,396	$2,742	$2,653
Other Operating Activities, Cash Flow Statement	$77	$6	$99	$93
Increase (Decrease) in Accounts Receivable	$10,327	$-8,697	$-701	$-867
Increase (Decrease) in Prepaid Expense and Other Assets	$-2,723	$4,328	$-1,144	$4,367
Increase (Decrease) in Accounts Payable	$273	$-119	$-468	$-1,094
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	$1,316	$-1,267	$-6,049	$525
IncreaseDecreaseInOperatingLeaseLiability	$-4,695	$-5,219	$-5,774	$-6,065
Increase (Decrease) in Deferred Revenue	$3,772	$9,884	$-18,836	$-3,396
Payments of Stock Issuance Costs	—	—	$8,100	$8,100

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("CCCC","financials")

Full statements spill as a table. For one cell: =jivedata("CCCC","Revenue") or =jivedata("CCCC","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.